Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 6:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 913 matching trials from the live ClinicalTrials.gov search.
Conditions
Age-Related Macular Degeneration
Interventions
AG-013,958
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
30
States / cities
Mesa, Arizona • Oro Valley, Arizona • Phoenix, Arizona + 27 more
Conditions
Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
AMD
Interventions
Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/ML, Anecortave Acetate Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Wet Age-Related Macular Degeneration
Interventions
PTK787, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
7
States / cities
Beverly Hills, California • Denver, Colorado • Tampa, Florida + 4 more
Completed Not applicable Interventional Accepts healthy volunteers

Comparative Effectiveness of Vitamin D and Repletion Strategies

NCT01524874
Conditions
Hypovitaminosis D, Insulin Resistance, Diabetes
Interventions
Vitamin D3
Dietary Supplement
Lead sponsor
Bastyr University
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Kailua-Kona, Hawaii • Kenmore, Washington
Not listed Not applicable Interventional Accepts healthy volunteers

Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals

NCT05763940
Conditions
Dry Eye Syndromes, Age-Related Macular Degeneration, Omega 3 Index
Interventions
OmegaBoost, Nature Made (soft gel), Nature Made (gummy)
Dietary Supplement
Lead sponsor
Western University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pomona, California
Conditions
Proliferative Diabetic Retinopathy, Macular Edema
Interventions
ranibizumab
Drug
Lead sponsor
Jumper, J. Michael, M.D.
Individual
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Francisco, California
Completed No phase listed Observational Accepts healthy volunteers

Brain Connectivity in Age-Related Macular Degeneration

NCT01996215
Conditions
Age-Related Macular Degeneration
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
50 Years to 90 Years
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Retinal Drusen, Age-related Macular Degeneration, Macular Degeneration
Interventions
Lumega-Z, AREDS2
Dietary Supplement
Lead sponsor
Guardion Health Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Conditions
Dry Age-related Macular Degeneration
Interventions
GT005
Drug
Lead sponsor
Gyroscope Therapeutics Limited
Industry
Eligibility
55 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Huntington Beach, California • Palo Alto, California + 29 more
Conditions
ROSAH
Interventions
DF-003
Drug
Lead sponsor
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Bethesda, Maryland • Durham, North Carolina • Salt Lake City, Utah
Conditions
Age Related Macular Degeneration, Geographic Atrophy
Interventions
Not listed
Lead sponsor
Carl Zeiss Meditec, Inc.
Industry
Eligibility
50 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Oakland, California • Jackson, Michigan
Conditions
Macular Degeneration
Interventions
intravitreal injection Lucentis (ranibizumab)
Drug
Lead sponsor
Retina Research Foundation
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Slingerlands, New York
Conditions
Neovascular Age-related Macular Degeneration
Interventions
AXT107 Low Dose, AXT107 Mid Dose, AXT107 High Dose
Drug
Lead sponsor
AsclepiX Therapeutics, Inc.
Industry
Eligibility
50 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Springfield, Massachusetts • St Louis, Missouri • Asheville, North Carolina + 1 more
Conditions
Macular Degeneration
Interventions
Abicipar Pegol, Ranibizumab, Sham Procedure
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
71
States / cities
Phoenix, Arizona • Tucson, Arizona • Encino, California + 61 more
Completed No phase listed Observational Accepts healthy volunteers

Functionally Validated Structural Endpoints for Early AMD

NCT04112667
Conditions
Age-related Macular Degeneration, Aging
Interventions
Normal Macular Health, Early Macular Degeneration, Young Normals
Other
Lead sponsor
Cynthia Owsley
Other
Eligibility
20 Years and older
Enrollment
556 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Dry Age-Related Macular Degeneration, Geographic Atrophy
Interventions
iPSC-derived RPE/PLGA transplantation
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 95 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Conditions
Alcohol Use Disorder, Retinal Dystrophies, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
Interventions
Oral disulfiram
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, New York
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Alpha Lipoic Acid in Geographic Atrophy

NCT02613572
Conditions
Age-Related Macular Degeneration
Interventions
alpha lipoic acid, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 90 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
Iowa City, Iowa • Teaneck, New Jersey • Eugene, Oregon + 2 more
Conditions
Age-Related Macular Degeneration
Interventions
SF0166 Topical Ophthalmic Solution
Drug
Lead sponsor
OcuTerra Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Fullerton, California • Mountain View, California + 9 more
Conditions
Eye Diseases, Macular Degeneration, Retinal Diseases, Retinal Degeneration, Neovascularization, Pathologic
Interventions
OPT-302, Lucentis™
Drug
Lead sponsor
Opthea Limited
Industry
Eligibility
50 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 11 more
Conditions
Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion (RVO)
Interventions
Iheezo, Lidocaine pledget
Drug
Lead sponsor
Retina Consultants of Delmarva
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Easton, Maryland
Conditions
Nonexudative Age-related Macular Degeneration
Interventions
Photobiomodulation (Gentlewaves, Warp 10)
Device
Lead sponsor
Merry, Graham, M.D.
Individual
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Oak Ridge, Tennessee
Conditions
Neovascular Age-related Macular Degeneration
Interventions
2.0 mg OPT-302, 2.0 aflibercept, Sham
Biological · Procedure
Lead sponsor
Opthea Limited
Industry
Eligibility
50 Years and older
Enrollment
998 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
60
States / cities
Phoenix, Arizona • Arcadia, California • Huntington Beach, California + 57 more